TOR Serine-Threonine Kinases
"TOR Serine-Threonine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
Descriptor ID |
D058570
|
MeSH Number(s) |
D08.811.913.696.620.682.700.931 D12.776.476.925
|
Concept/Terms |
TOR Serine-Threonine Kinases- TOR Serine-Threonine Kinases
- Kinases, TOR Serine-Threonine
- Serine-Threonine Kinases, TOR
- TOR Serine Threonine Kinases
- Target of Rapamycin Proteins
- Rapamycin Proteins Target
- mTOR Serine-Threonine Kinases
- Kinases, mTOR Serine-Threonine
- Serine-Threonine Kinases, mTOR
- mTOR Serine Threonine Kinases
- Mechanistic Target of Rapamycin Protein
- FK506 Binding Protein 12-Rapamycin Associated Protein 1
- FK506 Binding Protein 12 Rapamycin Associated Protein 1
- TOR Kinases
- FKBP12-Rapamycin Associated Protein
- Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Associated Protein
- Protein, FKBP12-Rapamycin Associated
- FKBP12-Rapamycin Complex-Associated Protein
- Complex-Associated Protein, FKBP12-Rapamycin
- FKBP12 Rapamycin Complex Associated Protein
- Protein, FKBP12-Rapamycin Complex-Associated
- RAFT-1 Protein
- Protein, RAFT-1
- RAFT 1 Protein
- Rapamycin Target Protein
- Protein, Rapamycin Target
- Target Protein, Rapamycin
- mTOR Protein
- Protein, mTOR
|
Below are MeSH descriptors whose meaning is more general than "TOR Serine-Threonine Kinases".
Below are MeSH descriptors whose meaning is more specific than "TOR Serine-Threonine Kinases".
This graph shows the total number of publications written about "TOR Serine-Threonine Kinases" by people in this website by year, and whether "TOR Serine-Threonine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2014 | 1 | 1 | 2 |
2016 | 0 | 2 | 2 |
2019 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles.
-
Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020 12 11; 11(12):1052.
-
MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment. Cell Death Dis. 2019 02 11; 10(2):120.
-
p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells. Cancer Cell. 2016 06 13; 29(6):935-948.
-
Programmed hyperphagia in offspring of obese dams: Altered expression of hypothalamic nutrient sensors, neurogenic factors and epigenetic modulators. Appetite. 2016 Apr 01; 99:193-199.
-
TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. J Clin Invest. 2014 Aug; 124(8):3566-78.
-
Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab. 2014 Jul 01; 20(1):133-44.
-
Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways. J Pharm Pharmacol. 2014 Jan; 66(1):62-72.
-
L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin. J Biol Chem. 2011 Oct 07; 286(40):34800-8.
-
Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res. 2007 Jan 01; 67(1):289-99.
-
Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. J Steroid Biochem Mol Biol. 2006 Aug; 100(4-5):107-16.